Keywords: CSL Behring, Berinert, FDA aproval, angioedema, genetic disorders

CSL Behring gains FDA approval of Berinert, for acute abdominal and facial attacks of hereditary angioedema

Article | 13 October 2009

Print This

The US Food and Drug Administration has granted marketing approval for CSL Behring, part of the Australian CSL group’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in